Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method formeasuring indirect costs of disease. J Health Econ. 1995;14:171–89.

    CAS  Article  Google Scholar 

  2. 2.

    Brouwer WBF, Koopsmanschap MA, Rutten FH. Productivity costs in cost effectiveness analysis: numerator or denominator? A further discussion. Health Econ. 1997;6:511–4.

    CAS  Article  Google Scholar 

  3. 3.

    Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. PharmacoEconomics. 2006;24(1):43–53.

    Article  Google Scholar 

  4. 4.

    Brouwer WBF. Too important to ignore: informal care givers and significant others. PharmacoEconomics. 2006;24(1):39–41.

    Article  Google Scholar 

  5. 5.

    Rappange DR, van Baal PHM, van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. Unrelated medical costs in life years gained: should they be included in economic evaluations of health care interventions? PharmacoEconomics. 2008;26(10):815–6.

    Article  Google Scholar 

  6. 6.

    Bobinac A, Van Exel J, Rutten F, Brouwer W. Caring for and caring about: disentangling the caregiving effect and the family effect. J Health Econ. 2010;29:549–56.

    Article  Google Scholar 

  7. 7.

    Wittenberg E, Prosser L. Disutility of Illness for caregivers and families: a systematic review of the literature. PharmacoEconomics. 2013;31(6):489–500.

    PubMed Central  Article  Google Scholar 

  8. 8.

    Sanders GD, Neumann PJ, Basu A, et al. Recommendations for the conduct, methodological practices, and reporting of cost effectiveness analyses: Second panel on cost effectiveness in medicine and health. JAMA. 2016;316(10):1093–103.

    Article  Google Scholar 

  9. 9.

    Canadian Agency for Drugs and Technology in Health Care Common Drug Review. https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr. Accessed 31 July 2018.

  10. 10.

    NICE Technology Appraisal Guidance. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance. Accessed 31 July 2018.

  11. 11.

    Australian Government Department of Health. Pharmaceutical Benefits Advisory Committee. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings. Accessed 31 July 2018.

  12. 12.

    Paulden M, O’Mahoney J, McCabe C. Determinants of change in the cost effectiveness threshold. Med Decis Making. 2017;37:264–76.

    Article  Google Scholar 

  13. 13.

    Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberations and the legitimacy problem for insurers. Philos Public Aff. 1997;26(4):303–50.

    Article  Google Scholar 

  14. 14.

    Tudor-Hart J. The inverse care law. Lancet. 1971;297:405–12.

    Article  Google Scholar 

  15. 15.

    Charles G, Stainton T, Marshall S. Young carers in Canada: the hidden costs and benefits of young caregiving. Vanier Institute of the Family, 2012 Vancouver. http://vanierinstitute.ca/wp-content/uploads/2015/12/CFT_2012-07-00_EN.pdf. Accessed 30 July 2018.

  16. 16.

    Cookson R, Mirelman AJ, Griffin S, et al. Using cost effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206–12.

    PubMed Central  Article  Google Scholar 

  17. 17.

    Lavalle TA, Wittenberg E, Lamarand K, Prosser LA. Variation in the spillover effects of illness on parents, spouses and children of the chronically ill. Appl Health Econ Health Policy. 2014;12(2):117–24.

    Article  Google Scholar 

  18. 18.

    Brouwer W. The inclusion of spillover effects in economic evaluation: not an optional extra. PharmacoEconomics. 2018. https://doi.org/10.1007/s40273-018-0719-1

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2017. https://doi.org/10.1002/hec.3633.

    Article  PubMed  Google Scholar 

  20. 20.

    Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2017. https://doi.org/10.1007/s40273-017-0585-2 (accessed 30 July 2018).

    Article  Google Scholar 

  21. 21.

    Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1–503 (v–vi).

    PubMed Central  Article  Google Scholar 

  22. 22.

    Lomas J, Claxton K, Martin S, Soares M. Resolving the “Cost-Effective but Unaffordable” Paradox: estimating the health opportunity costs of nonmarginal budget impacts. Value Health. 2018. https://doi.org/10.1016/j.jval.2017.10.006 (accessed 31 July 2018).

    Article  PubMed  Google Scholar 

  23. 23.

    Global Genes: FDA Orphan Drug Approvals 2018. https://globalgenes.org/raredaily/181474-2/. Accessed 31 July 2018.

  24. 24.

    Ebied AM, Cooper-deHoff RM. 2017 Banner Year for Drug Approvals. Am Med J. 2018. https://www.sciencedirect.com/science/article/pii/S0002934318302882. Accessed 31st July 2018 (in press).

  25. 25.

    Al-Janabi H, van Exel J, Brouwer W, Coast J. A framework for including family health spillovers in economic evaluation. Med Decis Mak. 2016;36(2):176–86.

    Article  Google Scholar 

  26. 26.

    Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ. 2015;24(1):1–7.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christopher McCabe.

Ethics declarations

Funding

No sources of funding were used to prepare this commentary.

Conflict of interest

Christopher McCabe has no conflicts of interest that are directly relevant to the content of this commentary.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McCabe, C. Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution. PharmacoEconomics 37, 457–460 (2019). https://doi.org/10.1007/s40273-018-0729-z

Download citation